Back to top
more

ARK Genomic Revolution ETF: (ARKG)

(Real Time Quote from BATS) As of Nov 19, 2026 01:12 PM ET

$40.65 USD

40.65
2,360,397

-0.61 (-1.48%)

Volume: 2,360,397

Zacks ETF Rank

This is our ETF rating system that serves as a timeliness indicator for ETFs over the next 6 months:

Zacks Rank Definition
1 Strong Buy
2 Buy
3 Hold
4 Sell
5 Strong Sell

See all the Top Ranked ETFs here - The complete list of all the top ranked ETFs

NA

Zacks News

Sweta Killa headshot

Top & Flop Zones of First-Half 2020 and Their ETFs

Inside the best and worst performing ETFs of first half.

Sweta Killa headshot

New GERM ETF Launched to Tap the Growing Biotech Sector

GERM invests in the hottest emerging biotechnology trends.

Sweta Jaiswal, FRM headshot

How Are Biotech ETFs Reacting to Coronavirus Treatment News?

Here we take a look at how the latest updates on drugs, antibody therapies and vaccines targeted at winning the coronavirus battle can affect biotech ETFs.

Sweta Killa headshot

5 ETFs Up More Than 20% in Three Months

Wall Street has been performing impressively with the major indices climbing to a 12-week high. The rally was mainly powered by optimism over a potential coronavirus vaccine as well as an uptick in the economic activities as lockdown measures loosen.

Sweta Jaiswal, FRM headshot

Biotech ETFs Soaring on COVID-19 Vaccine Progress

Novavax's latest progress in the Covid-19 vaccine development brings optimism to the Wall Street.

Sweta Killa headshot

Race for Coronavirus Vaccine Heats Up: Biotech ETFs to Gain

The COVID-19 pandemic has kept biotech players all over the world on their toes for a vaccine. This new opportunity has made the sector the most attractive one to investors.

Sanghamitra Saha headshot

Stocks & ETFs Beneficiaries of Coronavirus Vaccine Ramp-Up

Efforts in formulating a coronavirus vaccine are heating up. These stocks and ETFs look to be the largest beneficiaries.

Sweta Jaiswal, FRM headshot

Profit from the Genomics Market Momentum With These ETFs

Here we highlight some ETFs for gaining exposure to the genomics market that is currently buzzing with opportunities for investors to cash on.

Sweta Killa headshot

First-Mover Pandemic Disease Fight ETF On The Way

Pacer Financial has filed for Pacer BioThreat ETF to enjoy the first-mover advantage that provide investors an option to capitalize on the new opportunities triggered by coronavirus.

Sweta Jaiswal, FRM headshot

Ride Out the Coronavirus Mayhem With These ETF Areas

We discuss some ETF areas that investors can choose to invest for a smoother sail during the coronavirus pandemic.